Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a global biopharmaceutical holding company that primarily generates revenue from the sales of its oncology-focused portfolio of products. Their recent 1Q26 results, which included a topline beat and a raise in guidance, showcase the strength of their lead product, BRUKINSA, and its continued outpacing of competitors in market share. With potential near-term approvals for sonrotoclax in r/r MCL and BGB-16673 in r/r CLL, as well as updates on other promising programs, BeOne Medicines has a strong pipeline and a clearer path to future value and potential inflection points. However, risks include product commercial and supply chain issues, competition, and legal and regulatory hurdles.

Bears say

BeOne Medicines is facing strong competition in the oncology market and is highly reliant on the success of their drug Brukinsa, which currently makes up the majority of their revenue. While the company has shown strong growth in recent years, there is a risk that their pipeline may not fully deliver, as evidenced by delays in their BTK degrader drug. Furthermore, the high level of expenses for research and development and marketing, combined with a potential near-term commercial opportunity in the post-BTKi/post-BCL2i CLL setting, may put a strain on their financials and growth potential.

BeiGene Ltd (ONC) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 12 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $387, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $387, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.